Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive teen eczema registry launches to uncover disease patterns

NCT ID NCT06238765

Knowledge-focused Sponsor: CorEvitas Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This observational registry will follow 1,500 adolescents aged 12–15 with moderate-to-severe atopic dermatitis (eczema) across North America and Europe. Researchers aim to document the disease's natural history, how it's managed, and long-term outcomes. Participants will be under the care of a dermatologist and may be on various medications. The study does not test any new drug but hopes to improve understanding of this chronic skin condition in teens.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this registry could provide a clearer picture of how atopic dermatitis progresses and is managed in adolescents, potentially guiding better treatment approaches.
What could go wrong
As an observational study, it does not test a new treatment, so it won't directly improve outcomes. Results may take years and could be limited by the diversity of the participant group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Dec 2099

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects can enroll as early as age 10 and will be followed until the age of 18; therefore, the maximum duration a subject can be enrolled is \< 8 years.

Ages

10 to 15 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * To be eligible to participate in this registry, an individual must meet all the following criteria: 1. Has been diagnosed with moderate to severe atopic dermatitis by a dermatologist or a qualified healthcare provider 2. Is 10 - 15 years of age at the time of enrollment. 3. Subject has initiated or is initiating an enrollment-eligible medication at the time of enrollment Exclusion Criteria: * An individual who meets any of the following criteria will be excluded from participation in the registry: 1. Is participating or planning to participate in a blinded clinical trial for an AD drug. 2. Is unwilling or unable to provide standing height measurements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CorEvitas, LLC

    RECRUITING

    Waltham, Massachusetts, 02451, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.